Lancet Issue Dedicated To HIV/AIDS Ahead Of IAS Conference
The current issue of the Lancet is dedicated to HIV/AIDS, a theme meant to coincide with the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention taking place in Rome, Italy, July 17-20, according to a Lancet article (7/16).
In an editorial comment, Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS (BC-CfE) and former president of the IAS, writes, “The evidence is in: treatment is prevention,” according to CBC News (7/14). “Treatment dramatically prevents morbidity and mortality, HIV transmission, and tuberculosis. Furthermore, treatment prevents HIV transmission in vertical, sexual, and injection drug use settings; indeed, a very welcome double hat-trick. The challenge remains to optimize the impact of this valuable intervention. Failure to do so is not an option,” he concludes (7/16).
In an interview with NPR’s health blog “Shots,” Montaner said while incorporating treatment as prevention into country-wide strategies worldwide will “need more work” in a time of declining resources, “this should not be an excuse for policymakers, political leaders and others to say, ‘Oh, we need to wait until we solve this problem'” (Knox, 7/14).
Two studies in the issue report on rilpirivine, a second-generation antiretroviral drug that was approved by the FDA in May, according to Agence France-Presse. The studies conclude rilpirivine “is both safe and effective and its side effects are fewer and less severe compared with the widely-used efavirenz, or Sustiva,” the news agency reports (7/14).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.